Leerink Partnrs Has Positive Outlook for HIMS Q2 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Investment analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for shares of Hims & Hers Health in a report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $0.15 for the quarter, up from their previous estimate of $0.13. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q3 2025 earnings at $0.17 EPS, FY2025 earnings at $0.69 EPS, FY2026 earnings at $0.79 EPS and FY2027 earnings at $1.20 EPS.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same period in the prior year, the company posted $0.05 EPS. The firm’s quarterly revenue was up 110.7% compared to the same quarter last year.

Several other equities analysts also recently weighed in on the company. Morgan Stanley decreased their target price on Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday. Piper Sandler reiterated a “neutral” rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday. UBS Group restated a “mixed” rating on shares of Hims & Hers Health in a report on Tuesday. Finally, Truist Financial reduced their price objective on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $37.67.

Hims & Hers Health Price Performance

HIMS opened at $52.08 on Wednesday. The firm has a fifty day moving average price of $32.52 and a 200 day moving average price of $31.96. Hims & Hers Health has a 1 year low of $11.64 and a 1 year high of $72.98. The stock has a market cap of $11.57 billion, a P/E ratio of 118.35 and a beta of 1.84.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $43.28, for a total transaction of $314,169.52. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company’s stock, valued at approximately $8,379,051.28. This represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 650,500 shares of company stock valued at $25,790,311. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Allworth Financial LP lifted its position in shares of Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after acquiring an additional 334 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. SlateStone Wealth LLC boosted its position in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares during the period. Larson Financial Group LLC increased its stake in Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares in the last quarter. Finally, Blume Capital Management Inc. raised its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the period. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.